Sartorius Stedim Biotech Investor Relations

First-Half 2016 Results

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, discussed the company's results with analysts and Investors teleconference.

Download Presentation (1.4 MB)

Download Replay (11.5 MB)

First-Quarter 2016 Results

Full-Year 2015 Results

Facts & Figures

Download a brief overview of Sartorius Stedim Biotech and its current economic development.

Fact Sheet H1|2016 (261 KB)


First half of 2016: Sartorius Stedim Biotech continues strong performance

€ in millions unless otherwise specified1st half 20161st half 2015Growth in %Growth in %const. fx Sales revenue508.8422.020.622.3EMEA1231.5192.520.321.5Americas1187.9149.325.927.3Asia |...[more]

Date 25.07.2016     Category Corporate, Sartorius Stedim Biotech

Sartorius Stedim BioOutsource Introduces New Released N-Glycan Assay

In-depth profiling of IgG glycosylation coupled with ADCC assays enables generation of robust biosimilar comparability data [more]

Date 07.07.2016     Category Products, Sartorius Stedim Biotech

Sartorius Stedim Biotech Share (DIM)

Get in touch

Petra Kirchhoff

Andreas Theisen